| 摘要: |
| 目的分析三阴性乳腺癌患者miR-155的表达及在新辅助化疗中的意义。方法选取采用表柔比星+环磷酰胺方案新辅助化疗4个周期并成功实施乳腺癌改良根治术的女性三阴性乳腺癌患者23例，收集其在新辅助化疗前后的肿瘤组织标本和临床基本资料，采用RT-PCR法检测患者新辅助化疗前后癌组织的miR-155表达水平，并分析其在不同临床病理学特征患者中的表达情况。结果新辅助化疗后miR-155表达水平较化疗前明显降低，差异有统计学意义（P＜0.05）。Ki-67高表达的三阴性乳腺癌患者miR-155的表达水平显著高于Ki-67低表达的患者，差异有统计学意义（P＜0.05），而在不同年龄、原发灶分期、TNM分期、组织学分级、淋巴结转移情况患者之间比较差异均无统计学意义（均P＞0.05）。结论miR-155可作为判断三阴性乳腺癌新辅助化疗疗效及预后的肿瘤分子标志物，临床上miR-155、Ki-67高表达的三阴性乳腺癌患者可能从新辅助化疗中得到更多获益。 |
| 关键词: 三阴性乳腺癌 miR-155 Ki-67 临床病理学特征 |
| DOI：10.12056/j.issn.1006-2785.2017.39.19.2017-924 |
| 分类号: |
| 基金项目:浙江省医药卫生科技计划项目（2015KYB267） |
|
| Expression of miR-155 in triple-negative breast cancer and its significance in neoadjuvant chemotherapy |
|
|
|
the First Affiliated Hospital of Zhejiang Chinese Medical University
|
| Abstract: |
| Objective To investigate the expression of miR-155 in triple-negative breast cancer and its significance in neoadjuvant chemotherapy. Methods Twenty-three patients with triple-negative breast cancer, who received 4 cycles of neoadjuvant chemotherapy with epirubicin+cyclophosphamide regimen and successfully underwent radical mastectomy, were enrolled in the study. The tumor specimens and clinical data were collected before and after neoadjuvant chemotherapy. The expression of miR-155 in cancer tissue was detected by RT-PCR technique and the result was compared before and after neoadjuvant chemotherapy. The correlation of miR-155 expression with clinical and pathological features of patients was analyzed. Results The expression of miR-155 after neoadjuvant chemotherapy was significantly lower than that before neoadjuvant chemotherapy (P＜0.05). The expression of miR-155 in patients with Ki-67 overexpressing was significantly higher than that in those with Ki-67 low expression (P＜0.05). There was no significant difference in the expression of miR-155 among patients with different age, histological grade, clinical stage and lymph node metastasis status (all P ＞0.05). Conclusion The expression of miR-155 can be used as a molecular marker for the efficacy of neoadjuvant chemotherapy and the prognosis of
patients with triple-negative breast cancer. Clinically, triple-negative breast cancer patients with miR-155 and Ki-67 over-expression may benefit from neoadjuvant chemotherapy. |
| Key words: Triple-negative breast cancer miR-155 Ki-67 Clinico-pathological conference |
